Valuation : Personalis, Inc.

Market Cap 1.77B 1.52B 1.43B 1.31B 2.44B 168B 2.45B 16.99B 6.57B 85.91B 6.66B 6.51B 273B P/E 2026 *
-15.2x
P/E 2027 * -17.6x
Enterprise Value 1.6B 1.37B 1.29B 1.18B 2.2B 151B 2.21B 15.29B 5.92B 77.3B 5.99B 5.86B 246B EV / Sales 2026 *
19.3x
EV / Sales 2027 * 15.3x
Free-Float
73.85%
Yield 2026 *
-
Yield 2027 * -
1 day-3.49%
1 week-2.70%
Current month-1.07%
1 month+17.23%
3 months+65.34%
6 months+111.73%
Current year+108.54%
1 week 16.44
Extreme 16.44
17.35
1 month 13.68
Extreme 13.68
18.89
Current year 4.96
Extreme 4.955
18.89
1 year 4.96
Extreme 4.955
18.89
3 years 0.89
Extreme 0.8906
18.89
5 years 0.89
Extreme 0.8906
23.04
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 01/03/2023
Chief Executive Officer 65 30/12/2022
President 55 12/03/2026
Director TitleAgeSince
Director/Board Member 79 30/04/2019
Chairman 76 16/05/2022
Director/Board Member 72 05/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
15/07/26 Exercice

Chairperson

300,000 0.2865%
09/07/26 Exercice

Chief Executive Officer

300,000 0.2865%
29/06/26 Exercice

Chief Financial Officer

14,946 0.0143%
Change 5-day change 1-year change 3-year change Capi.($)
-3.49%-2.70%+212.03%+1,002.99% 1.77B
-2.70%-6.79%-4.33%+11.62% 48.01B
-1.29%-1.22%+404.92%+545.45% 44.44B
-3.20%+0.33%+38.11%+21.39% 42.67B
-1.89%-2.00%+1.45%+82.46% 39.96B
-1.72%-2.61%+13.09%+42.33% 32.75B
-0.17%+3.78% - - 17.74B
-0.07%+1.32%+20.08%+117.95% 16.49B
+0.39%-1.79%+11.76%+31.93% 14.38B
-2.68%-0.56%+73.31%+40.56% 13.4B
Average -1.69%-0.70%+85.60%+210.74% 27.16B
Weighted average by Cap. -1.84%-1.06%+85.70%+138.33%

Financials

2026 *2027 *
Net sales 82.47M 70.9M 66.71M 60.88M 114M 7.82B 114M 790M 306M 4B 310M 303M 12.72B 110M 94.75M 89.14M 81.35M 152M 10.45B 153M 1.06B 409M 5.34B 414M 405M 16.99B
Net income -115M -98.96M -93.1M -84.96M -159M -10.91B -159M -1.1B -427M -5.58B -432M -423M -17.75B -102M -87.66M -82.47M -75.26M -140M -9.67B -141M -977M -378M -4.94B -383M -374M -15.72B
Net Debt -178M -153M -144M -131M -245M -16.84B -246M -1.7B -659M -8.61B -667M -652M -27.39B -91.04M -78.28M -73.64M -67.2M -125M -8.63B -126M -873M -338M -4.41B -342M -334M -14.04B
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
08/09/26 US$16.60 -3.49% 2,548,580
04/09/26 US$17.20 +2.20% 2,522,867
03/09/26 US$16.83 +0.60% 2,494,050
02/09/26 US$16.73 -1.93% 2,227,164
01/09/26 US$17.06 +1.67% 3,619,033
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
16.60USD
Average target price
15.44USD
Spread / Average Target
-7.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSNL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!